Viewing Study NCT03857594


Ignite Creation Date: 2025-12-25 @ 1:41 AM
Ignite Modification Date: 2026-02-27 @ 12:49 AM
Study NCT ID: NCT03857594
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-03
First Post: 2018-10-23
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Integrative Sequencing In Germline and Hereditary Tumours
Sponsor: University Health Network, Toronto
Organization:

Study Overview

Official Title: Integrative Sequencing In Germline and Hereditary Tumours
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: INSIGHT
Brief Summary: This study will investigate the utility of integrative sequencing of individuals and families at risk of hereditary cancer syndromes and will uncover novel contributors to tumourigenesis. Integrative sequencing refers to:

1. Whole genome sequencing (WGS) of the germline (inherited) genome
2. Whole exome sequencing (WES) or targeted/panel sequencing of tumour(s) (somatic, tumour-specific mutations)
3. DNA methylation (methylome) analysis of tumour(s)
4. RNA sequencing (transcriptome) of tumour(s)

Eligible patients receiving genetic care at Princess Margaret Cancer Centre and the University Health Network may be approached by their genetic counsellor for participation in this study.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: